CBER (US Center for Biologics Evalation and Research) starts new programme to speed device approvals
This article was originally published in Clinica
Device companies need no longer fear that their review applications will get held up at the US FDA's Center for Biologics Evaluation and Research (CBER). From August 2, each device application will be assigned a CBER facilitator to shepherd it through the premarket process, according to Lillian Yin, special advisor to the centre's director.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.